CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
GSK256066drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00464568
NCT00464568Phase 2Completed
CompareCT.gov

A Randomised, Open, Placebo-controlled 5-way Crossover Trial of Single Doses of Intranasal GSK256066 in Subjects With Seasonal Allergic Rhinitis (SAR).

GlaxoSmithKline·interventional·Posted Apr 23, 2007·Updated Aug 20, 2018

In Brief

A Phase 2 clinical trial evaluating GSK256066 for Rhinitis, Allergic, Seasonal. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This current study is planned as a dedicated pharmacodynamic (effect of drug on the body) study to investigate the dose response in rhinitic subjects at doses where GSK256066 has been proven to work (200mcg) or expected to (50mcg) work. This study also aims to investigate the lower end of the predicted therapeutic range.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Seasonal
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 23, 2007
Enrollment StartMar 28, 2007
Primary CompletionMay 16, 2007
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 19.2 years ago

Interventions

GSK256066drug